India's Astrazeneca Pharma gains 2% on nod to import breast cancer drug
** Shares of Astrazeneca Pharma India Ltd ASTR.NS rise as
much as 2.58% to 3244.70 rupees
** Drugmaker gets permission from the Indian drug regulator
to import its breast cancer drug, Trastuzumak deruxtecan, for
sale and distribution in India
** Trading volume is 7168 shares as of 2:34 p.m. IST, 1.5x
the 30-day avg - Refinitiv data
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma India Receives Permission To Import And Sell Trastuzumab Deruxtecan For Additional Indication
Brief: Astrazeneca Pharma Says Bhavana Agrawal Resigns As CFO
Brief: Astrazeneca Pharma India Receives Permission To Import And Sell Benralizumab For Additional Indication
Brief: Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication
Brief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan